Large-cell lymphoma in four cats after FIP treatment with oral GS-441524
Journal of feline medicine and surgery · 2026
In plain language
Four cases of large-cell lymphoma were described among 202 cats enrolled in feline infectious peritonitis (FIP) treatment studies, after successful treatment of FIP with oral GS-441524. This observation does not show that the drug caused lymphoma: the cancer may have started developing before it was diagnosed. No FeLV genetic material integrated into cells in the blood was detected in any of the four cats, either at baseline or when lymphoma was diagnosed. The study does not establish the efficacy, toxicity or lymphoma risk of GS-441524 in cats infected with FeLV.
Scientific detail
This descriptive clinical series, published in the Journal of feline medicine and surgery in 2026, reports four cases of large-cell lymphoma among 202 cats enrolled in treatment studies for FCoV-associated feline infectious peritonitis (FIP). The cases were observed after successful FIP treatment with oral GS-441524. There was no concurrent comparator group for assessing lymphoma risk, and the authors state that the true annual incidence of feline lymphoma is unknown.
The authors could not fully exclude that lymphoma was already developing before its eventual diagnosis. The date of diagnosis therefore does not establish when the tumour began, limiting causal interpretation of its temporal relationship with antiviral exposure. Survivorship effects also complicate attribution, and owners' decisions regarding euthanasia might have influenced observed survival.
Table 1 reports that blood FeLV provirus was not detected in any of the four cats, either at baseline or at lymphoma diagnosis. These findings characterize the blood samples tested and provide no evidence of antiviral effects in FeLV-infected cats. The absence of a post-mortem examination in cat 4 prevented full evaluation of its neoplastic process; findings from cats that underwent necropsy cannot automatically be extended to that case.
The three claims in the source object are classified as level C evidence. This series provides a preliminary long-term safety observation in cats, not an investigation of antiviral activity against FeLV, and does not establish the efficacy, toxicity or lymphoma risk of GS-441524 in FeLV-infected cats. The supplied text is incomplete and does not include the supplementary files.
What we know
Four cases of large-cell lymphoma were described among 202 cats enrolled in FIP treatment studies, following successful treatment with oral GS-441524. Blood FeLV provirus was not detected in any of the four cats at baseline or at lymphoma diagnosis. Lymphoma could not be excluded as already developing before diagnosis, and the absence of a post-mortem examination in cat 4 prevented full evaluation of its neoplastic process. The three claims in the source object carry evidence level C.
What we don't know
Whether GS-441524 had a causal relationship with the lymphomas, and when they began developing, are not established. Without a concurrent comparator group, this series does not establish an increase in lymphoma risk. The authors state that the true annual incidence of feline lymphoma is unknown. Survivorship effects complicate attribution, and decisions about euthanasia might have influenced survival. Characterization of cat 4 remained incomplete. The efficacy, toxicity and lymphoma risk of GS-441524 in FeLV-infected cats are not established. The available text is incomplete and lacks the supplementary files.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The authors could not fully exclude that lymphoma development was already ongoing before its eventual diagnosis.
Excerpt verified in the source — verbatim, in the source's own language“It cannot be fully excluded that the development of LCL was already ongoing and that an earlier diagnostic work-up might have resulted in an earlier diagnosis in these cats.”
The timing of diagnosis does not establish the timing of tumour initiation, limiting causal interpretation of the temporal relationship with antiviral exposure.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
Blood FeLV provirus was not detected in any of the four cats at either baseline or lymphoma diagnosis.
Excerpt verified in the source — verbatim, in the source's own language“Blood FeLV provirus load (copies/ml) Not detected Not detected Not detected Not detected Not detected Not detected Not detected Not detected”
Table 1 reports paired baseline and lymphoma-diagnosis measurements for each cat. These findings characterize the reported blood samples; they do not provide evidence about antiviral effects in FeLV-infected cats.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The absence of a post-mortem examination in cat 4 prevented full evaluation of its neoplastic process.
Excerpt verified in the source — verbatim, in the source's own language“A limitation of the study is the absence of a post-mortem examination for cat 4, not allowing for full evaluation of the neoplastic process.”
Diagnostic characterization was incomplete in one case; findings from necropsied cats cannot automatically be extended to cat 4.
Provenance
Source: Large-cell lymphoma in four cats after successful treatment of feline infectious peritonitis with oral GS-441524: a novel clinical observation.
AVA